Background: SMYD3 is a histone methyltransferase implicated in cancer progression and is overexpressed in several malignancies, including gastric cancer (GC). Building on previous evidence linking SMYD3 to DNA damage repair, we investigated the molecular mechanisms through which SMYD3 regulates double-strand break (DSB) repair in GC and evaluated its therapeutic potential. Methods: In silico and in vitro analyses were performed to investigate the interactions between SMYD3 and key homologous recombination (HR) proteins, and to evaluate the ATM-mediated phosphorylation of SMYD3. Functional assays assessed the impact of pharmacological SMYD3 inhibition on HR and non-homologous end joining (NHEJ) repair pathways. Results: Mechanistically, SMYD3 interacted with key HR factors and facilitated chromatin remodeling at damaged sites. ATM phosphorylated SMYD3 at threonine 22, a modification required for HR complex assembly and validated in GC patient samples following neoadjuvant chemotherapy. Inhibition of SMYD3 abolished HR and partially impaired NHEJ. Combined inhibition of SMYD3 and PARP induced synthetic lethality in GC cells, spheroids, and patient-derived organoids, and overcame resistance to olaparib. Conclusions: These findings reveal the ATM-dependent molecular mechanism by which SMYD3 regulates DNA DSB repair, further supporting SMYD3 as a promising therapeutic target for precision oncology strategies in GC.

Targeting the DNA-repair chromatin-modifier protein SMYD3 as a novel epigenetics-based therapy for gastric cancer / De Marco, K., Latrofa, M., Forte, G., Lepore Signorile, M., Di Nicola, E., Sanese, P., Fasano, C., Disciglio, V., Candela, E., Coletta, S., Grossi, V., Simone, C.. - In: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. - ISSN 1756-9966. - 45:1(2026). [10.1186/s13046-026-03823-2]

Targeting the DNA-repair chromatin-modifier protein SMYD3 as a novel epigenetics-based therapy for gastric cancer

De Marco, Katia;Latrofa, Marialaura;Forte, Giovanna;Lepore Signorile, Martina;Candela, Erica;
2026

Abstract

Background: SMYD3 is a histone methyltransferase implicated in cancer progression and is overexpressed in several malignancies, including gastric cancer (GC). Building on previous evidence linking SMYD3 to DNA damage repair, we investigated the molecular mechanisms through which SMYD3 regulates double-strand break (DSB) repair in GC and evaluated its therapeutic potential. Methods: In silico and in vitro analyses were performed to investigate the interactions between SMYD3 and key homologous recombination (HR) proteins, and to evaluate the ATM-mediated phosphorylation of SMYD3. Functional assays assessed the impact of pharmacological SMYD3 inhibition on HR and non-homologous end joining (NHEJ) repair pathways. Results: Mechanistically, SMYD3 interacted with key HR factors and facilitated chromatin remodeling at damaged sites. ATM phosphorylated SMYD3 at threonine 22, a modification required for HR complex assembly and validated in GC patient samples following neoadjuvant chemotherapy. Inhibition of SMYD3 abolished HR and partially impaired NHEJ. Combined inhibition of SMYD3 and PARP induced synthetic lethality in GC cells, spheroids, and patient-derived organoids, and overcame resistance to olaparib. Conclusions: These findings reveal the ATM-dependent molecular mechanism by which SMYD3 regulates DNA DSB repair, further supporting SMYD3 as a promising therapeutic target for precision oncology strategies in GC.
2026
DNA damage response; Gastric cancer; Homologous recombination; PARP inhibitors; SMYD3
01 Pubblicazione su rivista::01a Articolo in rivista
Targeting the DNA-repair chromatin-modifier protein SMYD3 as a novel epigenetics-based therapy for gastric cancer / De Marco, K., Latrofa, M., Forte, G., Lepore Signorile, M., Di Nicola, E., Sanese, P., Fasano, C., Disciglio, V., Candela, E., Coletta, S., Grossi, V., Simone, C.. - In: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. - ISSN 1756-9966. - 45:1(2026). [10.1186/s13046-026-03823-2]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1780402
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact